黄连药性研究

Recent Progress of Drug Nature of Coptidis Rhizoma

对黄连药性研究进行了归纳、总结、分析和讨论,为以后黄连药性的研究提供新思路。采用不同的受试对象研究黄连药性各有优缺点,很难找到一个合适的受试对象。这些研究在某种程度上能论证黄连为寒药,但是建立寒性药物的评判标准仍是一条漫长之路。交叉学科的融入可能为未来研究黄连药性开启新的探索之门。DNA甲基化/去甲基化、染色质重塑、组蛋白修饰是应答机体内外环境条件变化而进行的表观遗传修饰方式。黄连作为一种干扰机体内环境变化的因素,可能反向调节机体内环境所引起的表观遗传修饰。因此,从表观遗传学角度研究黄连药性可能是未来研究的方向之一。

Drug nature of Coptidis Rhizoma was reviewed in the paper which provided a new idea for research on drug nature. It is difficult to find a suitable research subject for discussing nature of Coptidis Rhizoma although some subjects were adopted in many researches. Some studies demonstrated that Coptidis Rhizoma, in a way, was a cold-natured medicine. However, it is still a long way to establish a criterion of cold-natured medicine. The emergency of interdiscipline may open a new door for exploring drug nature of Coptidis Rhizoma in the future. Epigenetic modifications, such as DNA methylation/demethylation, chromatin remodeling and histone modification, often change along with both inner and outer environment. Coptidis Rhizoma as an outer environmental factor may reversely regulate epigenetic modifications which are caused by diseases. Therefore, epigenetics may provide a new field in researches of drug nature of Coptidis Rhizoma in the future.